Neurogene Inc
NGNE20.010USD
-0.060-0.30%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
295.65MMarket Cap
LossP/E TTM
More Details of Neurogene Inc Company
Neurogene Inc. is a clinical-stage biotechnology company. The Company, through its proprietary transgene regulation technology, Expression Attenuation via Construct Tuning (EXACT), is building a product portfolio of genetic medicines for rare neurological diseases with high unmet needs not otherwise addressable by conventional gene therapy. Its clinical-stage program, NGN-401, utilize the EXACT platform, which is in development for the treatment of Rett syndrome, a disease with a patient population that has a significant unmet need, and that ultimately progresses to substantial neurological and physical impairment and premature death. NGN-401 is being evaluated in female patients with Rett syndrome in a Phase 1/2 open-label, multi-center clinical trial that assesses the safety, tolerability, and efficacy of two doses of NGN-401 delivered using a one-time intracerebral ventricular (ICV) procedure. It is also developing NGN-101 for the treatment of CLN5 Batten disease.
Neurogene Inc Info
Ticker SymbolNGNE
Company nameNeurogene Inc
IPO dateMar 07, 2014
CEOMcMinn (Rachel L)
Number of employees107
Security typeOrdinary Share
Fiscal year-endMar 07
Address535 W 24Th Street
CityNEW YORK
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code10011
Phone18772375020
Websitehttps://www.neurogene.com/
Ticker SymbolNGNE
IPO dateMar 07, 2014
CEOMcMinn (Rachel L)
Company Executives of Neurogene Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Stuart Cobb, Ph.D.
Dr. Stuart Cobb, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
403.00
-94.40%
Mr. Rohan Palekar
Mr. Rohan Palekar
Independent Director
Independent Director
--
--
Mr. Robert Keith Woods
Mr. Robert Keith Woods
Independent Director
Independent Director
--
--
Dr. Sarah B. Noonberg, M.D., Ph.D.
Dr. Sarah B. Noonberg, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Robert A. Baffi
Dr. Robert A. Baffi
Independent Director
Independent Director
--
--
Dr. Cory Freedland
Dr. Cory Freedland
Independent Director
Independent Director
--
--
Dr. Rachel L. McMinn, Ph.D.
Dr. Rachel L. McMinn, Ph.D.
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
--
--
Ms. Christine Mikail Cvijic, J.D.
Ms. Christine Mikail Cvijic, J.D.
President, Chief Financial Officer
President, Chief Financial Officer
--
--
Ms. Julie Jordan, M.D.
Ms. Julie Jordan, M.D.
Chief Medical Officer
Chief Medical Officer
--
-100.00%
Name
Name/Position
Position
Shareholding
Change
Dr. Stuart Cobb, Ph.D.
Dr. Stuart Cobb, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
403.00
-94.40%
Mr. Rohan Palekar
Mr. Rohan Palekar
Independent Director
Independent Director
--
--
Mr. Robert Keith Woods
Mr. Robert Keith Woods
Independent Director
Independent Director
--
--
Dr. Sarah B. Noonberg, M.D., Ph.D.
Dr. Sarah B. Noonberg, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Robert A. Baffi
Dr. Robert A. Baffi
Independent Director
Independent Director
--
--
Dr. Cory Freedland
Dr. Cory Freedland
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, Dec 18
Updated: Thu, Dec 18
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Samsara BioCapital, LLC
11.09%
RTW Investments L.P.
8.80%
Redmile Group, LLC
8.39%
Casdin Capital, LLC
8.36%
EcoR1 Capital, LLC
8.21%
Other
55.16%
Shareholders
Shareholders
Proportion
Samsara BioCapital, LLC
11.09%
RTW Investments L.P.
8.80%
Redmile Group, LLC
8.39%
Casdin Capital, LLC
8.36%
EcoR1 Capital, LLC
8.21%
Other
55.16%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
37.53%
Hedge Fund
27.90%
Investment Advisor
18.86%
Venture Capital
11.16%
Research Firm
9.14%
Individual Investor
8.50%
Bank and Trust
0.08%
Pension Fund
0.06%
Insurance Company
0.02%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
202
15.71M
110.06%
-3.24M
2025Q2
207
17.85M
125.13%
-2.21M
2025Q1
216
18.11M
126.54%
-1.93M
2024Q4
211
17.68M
118.99%
+934.89K
2024Q3
193
15.29M
117.57%
+50.95K
2024Q2
185
14.71M
113.65%
+656.15K
2024Q1
190
13.87M
122.85%
+4.51M
2023Q4
186
10.89M
99.88%
+9.09M
2023Q3
208
1.31M
59.57%
-490.20K
2023Q2
215
1.27M
59.11%
-309.84K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Samsara BioCapital, LLC
1.72M
12.03%
--
--
Jun 30, 2025
RTW Investments L.P.
1.36M
9.55%
+13.80K
+1.02%
Jun 30, 2025
Redmile Group, LLC
1.28M
8.95%
-31.39K
-2.40%
Jun 30, 2025
Casdin Capital, LLC
1.30M
9.08%
--
--
Jun 30, 2025
EcoR1 Capital, LLC
1.27M
8.91%
--
--
Jun 30, 2025
McMinn (Rachel L. Ph.D.)
1.25M
8.76%
-71.49K
-5.41%
Apr 16, 2025
Baker Bros. Advisors LP
991.69K
6.95%
-494.51K
-33.27%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
820.54K
5.75%
-125.78K
-13.29%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Virtus LifeSci Biotech Clinical Trials ETF
1.14%
iShares Neuroscience and Healthcare ETF
0.42%
Franklin Genomic Advancements ETF
0.21%
iShares Micro-Cap ETF
0.06%
Invesco Nasdaq Biotechnology ETF
0.05%
Fidelity Enhanced Small Cap ETF
0.05%
ProShares Ultra Nasdaq Biotechnology
0.04%
iShares Biotechnology ETF
0.04%
Avantis US Small Cap Equity ETF
0.03%
iShares Russell 2000 Value ETF
0.01%
View more
Virtus LifeSci Biotech Clinical Trials ETF
Proportion1.14%
iShares Neuroscience and Healthcare ETF
Proportion0.42%
Franklin Genomic Advancements ETF
Proportion0.21%
iShares Micro-Cap ETF
Proportion0.06%
Invesco Nasdaq Biotechnology ETF
Proportion0.05%
Fidelity Enhanced Small Cap ETF
Proportion0.05%
ProShares Ultra Nasdaq Biotechnology
Proportion0.04%
iShares Biotechnology ETF
Proportion0.04%
Avantis US Small Cap Equity ETF
Proportion0.03%
iShares Russell 2000 Value ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Dec 14, 2023
Merger
4→1
Dec 14, 2023
Merger
4→1
Dec 14, 2023
Merger
4→1
Dec 14, 2023
Merger
4→1
Sep 22, 2023
Merger
5→1
Sep 22, 2023
Merger
5→1
Date
Type
Ratio
Dec 14, 2023
Merger
4→1
Dec 14, 2023
Merger
4→1
Dec 14, 2023
Merger
4→1
Dec 14, 2023
Merger
4→1
Sep 22, 2023
Merger
5→1
Sep 22, 2023
Merger
5→1
Sep 22, 2023
Merger
5→1
Sep 22, 2023
Merger
5→1
FAQs
Who are the top five shareholders of Neurogene Inc?
The top five shareholders of Neurogene Inc are:
Samsara BioCapital, LLC holds 1.72M shares, accounting for 12.03% of the total shares.
RTW Investments L.P. holds 1.36M shares, accounting for 9.55% of the total shares.
Redmile Group, LLC holds 1.28M shares, accounting for 8.95% of the total shares.
Casdin Capital, LLC holds 1.30M shares, accounting for 9.08% of the total shares.
EcoR1 Capital, LLC holds 1.27M shares, accounting for 8.91% of the total shares.
Samsara BioCapital, LLC holds 1.72M shares, accounting for 12.03% of the total shares.
RTW Investments L.P. holds 1.36M shares, accounting for 9.55% of the total shares.
Redmile Group, LLC holds 1.28M shares, accounting for 8.95% of the total shares.
Casdin Capital, LLC holds 1.30M shares, accounting for 9.08% of the total shares.
EcoR1 Capital, LLC holds 1.27M shares, accounting for 8.91% of the total shares.
What are the top three shareholder types of Neurogene Inc?
The top three shareholder types of Neurogene Inc are:
Samsara BioCapital, LLC
RTW Investments L.P.
Redmile Group, LLC
Samsara BioCapital, LLC
RTW Investments L.P.
Redmile Group, LLC
How many institutions hold shares of Neurogene Inc (NGNE)?
As of 2025Q3, 202 institutions hold shares of Neurogene Inc, with a combined market value of approximately 15.71M, accounting for 110.06% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -15.07%.
What is the biggest source of revenue for Neurogene Inc?
In --, the -- business generated the highest revenue for Neurogene Inc, amounting to -- and accounting for --% of total revenue.
